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Background: The chemokine CXCL16 and its receptor CXCR6 are expressed by a variety of immune cells and have
been shown to influence angiogenesis. The expression of CXCR6 and CXCL16 has been examined in numerous
human cancers; however no studies have yet investigated their influence on prognosis in non-small cell lung cancer
(NSCLC). We aimed to explore their prognostic significance in NSCLC, in addition to examining associations with
previously investigated markers.
Methods: Resected tumor tissue from 335 consecutive unselected stage I-IIIA NSCLC patients (1990–2005) were
collected. Immunohistochemistry was used to evaluate the expression of CXCR6 and CXCL16 on tissue microarrays.
In vitro, NSCLC cells (NCI-H460, A549 cells) were transfected with CXCL16 siRNA to examine effects on proliferation.
Results: In univariate analysis, ↑ stromal cell CXCL16 expression was a significant positive prognostic factor
(P = 0.016). CXCR6 was expressed in cancer cells, but did not show any prognostic impact. In the multivariate
analysis, combined ↑cancer, and ↑stromal cell CXCL16 expression was an independent positive prognostic factor
when compared to ↓stromal and ↓cancer cell expression (HR: 0.42; 95 % CI: 0.20–0.88; P = 0.022). Knockdown of
CXCL16 by siRNA resulted in accelerated proliferation of NSCLC cell lines.
Conclusion: We have shown that combined ↑cancer and ↑stromal cell CXCL16 expression is an independent
positive prognostic factor in NSCLC. Further studies are warranted to elucidate the biological mechanism
underlying this finding.Background
Lung cancer is the leading cause of cancer death world-
wide [1]. Non-small cell lung cancer (NSCLC) is the
predominant form of lung cancer, representing 80–85 %
of new cases. Despite advances in treatment, NSCLC
mortality remains high as the majority of patients
present with advanced disease and are not candidates
for curative surgery. The 5-year survival rates for
surgically resected NSCLC range from 73 % to 24 %* Correspondence: sigurd.hald@uit.no
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ultimately relapse and succumb to metastatic disease.
New biological markers may improve outcome predic-
tion and selection of additional therapy in NSCLC.
Chemokines are chemotactic cytokines originally rec-
ognized for their ability to induce leucocyte migration
[3], are now known to be involved in a variety of patho-
logic and physiologic processes [4]. In cancer biology,
chemokines are associated with tumor progression [5],
metastasis [6] and angiogenesis [7], in addition to
leukocyte recruitment to the tumor microenvironment
[8]. Chemokines have been recognized as targets in cancer
therapy as well as potential agents for immunotherapy,is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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progression of cancer [9, 10] .
The chemokine receptor CXCR6 was originally identi-
fied as a co-receptor for the human immunodeficiency
virus (HIV) [11–13] and is expressed on subsets of
CD4+ and CD8+ T-cells [14], plasma cells [15] and
NK-cells [16]. Its ligand CXCL16, one of two chemo-
kines known to exist in both transmembrane and sol-
uble forms, facilitates the recruitment, and adhesion of
CXCR6 expressing cells [17, 18] and is also a scavenger
receptor for oxidized low-density lipoprotein [19].
CXCL16 is expressed on macrophages, dendritic cells,
B-cells, and monocytes [17, 20], but is also constitutively
expressed on epidermal keratinocytes [21], bronchial epi-
thelial cells [22] and renal podocytes [23]. In addition to
their roles in leucocyte recruitment and inflammation,
CXCR6, and CXCL16 have been shown to influence
angiogenesis [24, 25].
The expression of CXCL16 and CXCR6 has been in-
vestigated in a variety of human cancers [26] and corre-
lated with both improved [27] and reduced survival [25].
An aptamer- found reduced expression of CXCL16 in
NSCLC tissue compared to normal controls suggesting
CXCL16 as a novel biomarker in NSCLC [28]. However,
no studies have examined the impact by CXCR6 and
CXCL16 on lung cancer survival. Hence, we examined
the expression of CXCL16 and CXCR6 and their rela-
tions to prognosis in 335 unselected patients with
NSCLC, and investigated possible relationships with our
previously studied immunologic and angiogenic markers.
Besides, the influence of CXCL16 on NSCLC cell prolif-
eration was examined in vitro.
Methods
Patients
Patients surgically resected for stage I-IIIA NSCLC at
the University Hospital of North Norway (UNN) and
Nordland Hospital (NH) from 1990 through 2005 were
included in this study. Of the 371 patients identified
from the hospital databases, a total of 36 were excluded
due to inadequate paraffin-embedded fixed tissue blocks
(n = 13), other malignancy within 5 years prior to
NSCLC diagnosis (n = 13), or radio-, or chemotherapy
prior to surgery (n = 10). Thus, 335 patients were in-
cluded in the study, 159 from UNN, and 176 from NH.
Adjuvant chemotherapy had not been introduced in
Norway during this period (1990–2004). This study in-
cludes follow up data as of January 2011. Patients were
staged according to the revised 7th edition of UICC
TNM classification of lung cancer [2]. The study was
approved by The Norwegian Data Inspectorate and The
Regional Committee for Medical and Health Research
Ethics. Information about the study and subsequent
written consent from patients was considered. However,as this was a retrospective study with more than half of
patients deceased, with the rest of the patients having to
be reminded about the death rate of the disease and the
possible raising of unrealistic hope for the individual,
The Norwegian Data Inspectorate, and The Regional
Committee for Medical and Health Research Ethics
waived the need for consent. All patient data were anon-
ymized after collecting the clinicopathological variables
for each patient and before doing the statistical analyses.
Microarray construction
Two pathologists (S.Al-S and K.Al-S) reviewed the
pathological specimens. Two representative areas of can-
cer cells (neoplastic epithelium) and two from the tumor
surrounding stroma were marked on the paraffin donor
blocks. Using a 0.6 mm-diameter stylet, one core from
each marked area was transferred to a recipient block.
Normal lung tissue localized distant from the tumor, in
addition to samples from 20 patients without a diagnosis
of cancer were used as controls. To include all tissue
samples, a total of 9 TMAs were constructed. Multiple
4-μm-sections were cut with a Micron microtome
(HM355S) before antibody staining for immunohisto-
chemical analysis. The detailed methodology has been
previously reported [29].
Immunohistochemistry
CXCR6 (goat polyclonal, ab125115, 1:100), and CXCL16
(rabbit polyclonal, ab101404, 1:100) antibodies from
Abcam were used in the study. The antibodies were vali-
dated by the manufacturer for immunohistochemistry
(IHC) on paraffin-embedded material. In addition, in-
house validation by Western blot analysis was performed
(Fig. 1). Cut sections were deparaffinized with xylene
and rehydrated with ethanol. Antigen retrieval was done
by placing the sections in 0.01 M citrate buffer pH 6.0
before microwave heating for 20 minutes at 450 W.
Endogenous peroxidase was blocked by incubation in
3 % H202 for 10 minutes. Sections were blocked in 5 %
goat or rabbit serum for 1 hour before overnight incuba-
tion with the primary antibodies at 4 °C. The primary
antibodies were visualized by adding a secondary biotin-
conjugated antibody followed by an Avidin/Biodin/Per-
oxidase complex (Vectastain ABC Elite-kit, Vectastain),
and substrate (Vector NovaRed, Vectastain). As negative
staining controls, the primary antibodies were replaced
with the primary antibody diluent. All slides were coun-
terstained with haematoxylin to visualize the nuclei.
Scoring of Immunohistochemistry
Sections were scored semi-quantitatively by two experi-
enced pathologist (S.Al-S and E.R). The dominant stain-
ing intensity of stromal and cancer cells was scored as:
0 = negative, 1 = weak, 2 = intermediate, 3 = strong. For
Fig. 1 Antibody validation. In the lung adenocarcinoma cell line
A549 we detected protein bands corresponding to CXCL16 and
CXCR6. Transfection with specific siRNAs caused a marked decrease
of protein expression. Equal loading was ensured by staining
for beta-actin
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also scored, in the following manner: 0 = no cells show-
ing positivity, 1 = less than 25 % positivity, 2 = 25-50 %
positivity, and 3 = 50-100 % positivity. CXCL16 dis-
played homogenous staining in cancer cells, while
CXCR6 did not show positivity in stromal cells. For
some patients, one, or both of the stromal or cancer
tissue cores were missing. Favoring a conservative ap-
proach, we chose not to extrapolate scores from single
cores. Consequently, all reported marker expressions
are based on the evaluation of two separate tissue
cores.
The mean intensity score of duplicate cores from each
patient was calculated. For stromal CXCL16 and cancer
cell CXCR6, this intensity score was combined with the
mean density score. Finally, protein expression was
dichotomized into high and low expression. High cancer
cell CXCR6 was defined as a score ≥5.5, while high
cancer, and stromal cell CXCL16 was defined as scores
≥2.5 and ≥3, respectively. The stromal, and cancer cell
CXCL16 co-expression variable was constructed by
combining the dichotomized cancer and stromal cell
CXCL16 variables.Western blotting
The specificity of the CXCL16 and CXCR6 antibodies
was investigated by Western blotting. Cell lysates were
incubated with NuPAGE LDS Sample Buffer (Life
Technologies, USA) for 5 minutes at 85 °C, sonicated
briefly, and run on a NuPAGE® 4-12 % Bis Tris Gel
(cat#NP0322, Life Technologies, USA). Blotting was
performed on a Hybond nitrocellulose membrane (cat#
RPN2020D, GE Healthcare) using the NuPAGE blot-
ting system (Life Technologies, USA). The membrane
was incubated with Odyssey blocking buffer (cat# 927–
40000, LI-COR Biosciences, Germany) for 1 hour at
room temperature. Primary and secondary antibodies
were diluted in the blocking buffer. Anti-CXCL16 anti-
body (cat# 101404) was used in the dilution of 1:500,
anti-CXCR6 in the dilution 1:500 (cat# 125115) and
anti-actin (cat#A2066, Sigma) 1:2000. IRDye CW sec-
ondary antibodies (cat# 926–32213 and 926–68073,
LI-COR, Germany) were used in dilution 1:10000.
Molecular weight markers used were SeeBlue Plus 2
(cat# LC5925, Life Technologies, USA), and Magic
Mark XP (cat# LC5602, Life Technologies, USA). Im-
ages were acquired on the ODYSSEY Sa Infrared Im-
aging System (LI-COR, Germany).
Cell cultures
NCI-H460 cells (ATCC#HTB-177) were grown in RPMI-
1640 media (21875–034, Gibco), A549 cells (ATCC#
CCL-185) were grown in Ham’s F-12 K (Kaighn’s) media
(21127–022, Gibco). Media for all cell lines contained
10 % fetal calf serum (Biochrome, Berlin, Germany), and
1 % of mixed 100 U/ml penicillin and 100 mg/ml strepto-
mycin (Sigma, cat#P0781, Sigma-Aldrich, St. Louis, MO).
RNA interference
Cells were transfected either in 6-well plates (for anti-
body specificity validation) or in E-plates 16 (Roche, cat#
05469830001) with human CXCL16 Silencer Select
siRNA (Ambion, s33807), or CXCR6 Silencer Select
siRNA (Ambion, s20963) using Lipofectamine 2000
(Invitrogen, cat# 11668–027, Carlsbad, CA) according
to the manufacturer’s recommendations. A scrambled
negative control siRNA was included in all experi-
ments (Silencer Negative Control #2 siRNA, Ambion,
Austin, TX). BLOCK-iT™ Fluorescent Oligo Reagent
(cat# 2013, Invitrogen) was used for transfection effi-
ciency control. Cells were harvested 24 hours after
siRNA transfection.
Proliferation assay
NCI-H460 and A549 cells were trypsinized briefly until
detached. Cells were resuspended in complete growth
media and counted. Optimal cell number per well (5000)
was determined in initial titration experiments. According
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were seeded in duplicates into E-plates 16 (Roche, cat#
05469830001) after baseline measurement. Plates were in-
cubated for 1 hour at room temperature, and then placed
into the RTCA DP instrument (Roche, cat# 05469759001)
located in an incubator preserving same temperature and
CO2 concentration as were used for routine cultivation of
the cells. siRNA transfection mix was added to the cells
6 hours after seeding, and left there for 4 hours. After that,
transfection mix was replaced with regular growth media.
Cell index (arbitrary unit reflecting the cell-sensor imped-
ance) was measured every 15 minutes during the first
4 hours for better resolution at attachment and spreading
phase. Further measurements were taken every 30 mi-
nutes. Doubling times were calculated with RTCA soft-
ware 1.2 (Roche). At least three independent experiments
were performed.
Statistical Methods
The Kaplan-Meier method was used to analyze the asso-
ciation between marker expression and disease-specific
survival (DSS), which was determined from the date of
surgery to the time of lung cancer death. The statistical
significance of differences between survival curves was
assessed with the log-rank test. Correlation assessments
between marker expression and other variables was
done using Spearman’s correlation test. Only variables
with significant P-values from the univariate analyses
were entered into the multivariate analysis, using the
Cox proportional hazards model (backward stepwise,
probability for stepwise entry, and removal set at 0.05
and 0.10). Statistical significance of the cell prolifera-
tion assays was determined using a two-sided Student’s




We used Western blotting to verify the specificity of the
CXCL16 and CXCR6 antibodies (Fig. 1) as described.
The molecular weight of the detected protein (strongest
bands) corresponded well with the predicted weight and
data provided by the manufacturers. The weaker extra
bands may represent chemically modified or degraded
proteins, or products of alternative splicing. siRNAs
targeted against CXCL16 and CXCR6 caused marked
decrease in the intensity of the bands, compared to
scrambled control siRNA. This confirms the specificity
of the used antibodies.
Patient characteristics
The demographic and clinical characteristics of the pa-
tients are presented in Table 1. The median patient age
was 67 (range 28–85) and the majority were male (76 %).Nearly all patients (96 %) were present or previous
smokers. The median follow-up was 105 months (range
73 – 234). There were 191 squamous cell carcinomas
(SCC), 113 adenocarcinomas (AC) and 31 large-cell car-
cinomas (LCC).
Marker expression and correlations
The expression of CXCL16 was predominantly cytoplas-
mic, while CXCR6 exhibited membranous staining
(Fig. 2). CXCL16 was expressed in both stromal and
cancer cells, whereas CXCR6 was only expressed in can-
cer cells (table 2). The stromal cells displaying positivity
for CXCL16 were fibroblasts, endothelial cells, macro-
phages, and plasma cells. Of the controls (20 patients
without a diagnosis of cancer), 50 % showed varying de-
grees of positivity for CXCR6 while 100 % showed strong
positivity for CXCL16. There were no significant correla-
tions between CXCR6 or CXCL16 and adaptive im-
munological (CD4, CD8, CD20), innate immunological
(CD68, CD56, CD1A), or angiogenic (vascular endothe-
lial growth factors and receptors, platelet derived growth
factors, and receptors and fibroblast growth factor-2 and
receptor-1) markers (data not shown). For both CXCR6
and CXCL16 the correlations with clinicopathological
factors were only weak or not significant (r < 0.2). A cor-
relation was observed between stromal and cancer cell
CXCL16 expression (r = 0.368, P < 0.01), however no sig-
nificant correlation was observed between CXCR6 and
CXCL16 in cancer cells.
Univariate analysis
The prognostic impacts of clinicopathologic variables
on DSS are given in Table 1. WHO Performance status
(P = 0.016), histology (P = 0.028), differentiation (P < 0.001),
surgical procedure (P = 0.007), pathological stage (P < 0.001),
tumor stage (P < 0.001), nodal stage (P < 0.001) and vascu-
lar infiltration (P <0.001) were significant prognosticators.
The influence of marker expression on survival is pre-
sented in Table 2. High CXCL16 expression in stromal
cells was significantly associated with an improved DSS
(P = 0.016, Fig. 3a), with similar trends observed for each
hospital separately (NH, P = 0.045; UNN, P = 0.137). The
combination of high stromal and high cancer cell
CXCL16 was also significantly associated with an im-
proved DSS (P = 0.016, Fig. 3b). Cancer cell CXCR6 and
CXCL16 did not have significant impact on survival in
univariate analyses.
Multivariate analysis
Significant clinicopathologic variables were entered into
multivariate analysis in two separate models, one with
stromal CXCL16 expression variable (model 1) and one
with the co-expression variable of cancer and stromal
cell CXCL16 (model 2).
Table 1 Prognostic clinicopathologic variables as predictors of disease-specific survival in 335 NSCLC-patients
Characteristics Patients N, (%) Median survival (months) 5-year survival (%) P
Age .421
≤65 years 156 (47) 98 56
>65 years 179 (53) NR 60
Sex .220
Female 82 (24) 190 64
Male 253 (76) 98 56
Smoking status .257
Never 15 (5) 19 43
Previous 105 (31) 84 55
Present 215 (64) NR 60
Performance status .016
0 197 (59) NR 63
1 120 (36) 64 52
2 18 (5) 25 33
Weight loss .759
<10 % 303 (90) 190 58
>10 % 32 (10) 98 57
Histology .028
Squamous cell carcinoma 191 (57) NR 66
Adenocarcinoma 113 (34) 54 46
Large cell carcinoma 31 (9) 98 56
Differentiation <.001
Poor 138 (41) 47 47
Moderate 144 (43) 190 65
Well 53 (16) NR 68
Surgical procedure 0.007
Wedge + Lobectomy 243 (73) 190 62
Pneumectomy 92 (27) 37 47
Pathological stage <.001
pI 157 (47) NR 72
pII 136 (41) 62 51
pIIIA 42 (12) 17 24
Tumor stage <.001
1 85 (25) 190 75
2 188 (56) 84 57
3 62 (19) 25 37
Nodal stage <.001
0 232 (69) NR 67
1 76 (23) 35 43
2 27 (8) 18 18
Surgical margins .374
Free 307 (92) 190 59
Not free 28 (8) 47 48
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Table 1 Prognostic clinicopathologic variables as predictors of disease-specific survival in 335 NSCLC-patients (Continued)
Vascular infiltration <.001
No 284 (85) 190 62
Yes 51 (15) 27 33
NR, not reached; NCSLC, non-small cell lung cancer
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formance status, vascular infiltration, and histology were
independent prognostic variables in both models
(Table 3).
In model 1, high expression of stromal CXCL16
was an independent positive prognostic factor (HR:
0.55; 95 % CI: 0.35 – 0.87, P = 0.011). The combined
high expression of CXCL16 in stromal and cancer
cells was an independent positive prognostic factor
for DSS in model 2 (HR: 0.42; 95 % CI: 0.20 – 0.88,
P = 0.022) when compared to the combined low
expression.
Cell proliferation
The increased survival seen in patients with combined
high CXCL16 expression in cancer and stromal cells led
us to investigate the effect of CXCL16 on cell prolifera-
tion. We employed the xCELLigence platform (Roche)
which facilitates studying of cell proliferation in real
time. This is a micro electric assay based on changing
impedance of bottom electrodes in presence of the cells.
Attachment and initial spreading of the cells typically
took 3–6 hours, after which cells were transfected with
siRNAs. We repeatedly observed that knockdown of
CXCL16 with siRNA caused activation of proliferation
compared to the negative scrambled control (P < 0.001,
Fig. 4). This was evident both from the growth curves
and from the doubling time calculations. The same ef-
fect was observed in two different NSCLC cell lines:
A549 and NCI-H460.Fig. 2 Immunohistochemical analyses of cancer and stromal cell CXCL16 e
expression; (b) Cancer cell CXCL16 low expression; (c) stromal CXCL16 high
high expression; (f) Cancer cell CXCR6 low expression; (g) Normal lung CXCDiscussion
We present the first study on the prognostic impact of
the chemokines CXCL16 and CXCR6 in lung cancer. To
our knowledge, this is also the first study examining
their expression in the tumor surrounding stroma in
addition to the epithelial cancer cells. Utilizing TMA
methodology on an unselected NSCLC cohort from two
hospitals, we show that high stromal CXCL16 expression
as well as combined high stromal/cancer cell expression
of CXCL16 is associated with a favorable DSS. The pat-
terns of increased, intermediate, and reduced CXCL16
expression showed 5-year survival rates of 71 %, 58 %
and 48 %, respectively. Supporting our findings, a
siRNA-mediated knockdown of CXCL16 resulted in ac-
celerated cell proliferation in two different NSCLC cell
lines.
The impact of CXCL16 and CXCR6 expression on sur-
vival varies markedly between different malignancies. In
colorectal cancer, Hojo et al. showed that high levels of
CXCL16 expression in tumors was a positive prognostic
factor and was correlated with increased levels of tumor-
infiltrating lymphocytes [30]. Similarly, radiation induced
CXCL16 expression stimulated the recruitment of anti-
tumor CD8 + cells in a murine model of breast cancer
[31]. We have previously shown that infiltrating lympho-
cytes are strongly associated with improved survival in
NSCLC [32, 33], but we found no correlation between
markers of tumor-infiltrating lymphocytes and CXCL16
levels in cancer cells or tumor stroma. If CXCL16 plays
a role in leukocyte recruitment in NSCLC, this is notxpression and cancer cell CXCR6 in NSCLC. (a) Cancer cell CXCL16 high
expression; (d) stromal CXCL16 low expression; (e) Cancer cell CXCR6
L16 expression; (h) Normal lung CXCR6 expression
Table 2 CXCL16 and CXCR6 expression as predictors of disease-specific survival in 335 NSCLC patients
Characteristics Patients, N (%) Median survival (months) 5-year survival (%) P
CXCL16
Cancer cells .080
High 48 (14) NR 67
Low 227 (68) 98 56
Missing 60 (18)
Stromal cells .016
High 258 (77) 57 48




High 41 (12) 190 73
Low 245 (73) 122 55
Missing 49 (15)
CXCL16
Cancer cells + .016
stromal cells combined
High/High 43 (13) NR 71
High/Low 182 (54) 190 58
Low/Low 41 (12) 47 48
Missing 69 (21)
NR, not reached; NCSLC, non-small cell lung cancer
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markers in the resected tissue. In gastric cancer, Xing
et al. found nuclear CXCL16 expression to be related to
improved survival and reduced cancer aggressiveness
[34]. We did, however, not observe nuclear staining for
CXCL16 in our TMAs.Fig. 3 a. Disease specific survival curve according to expression of stromal
according to the co-expression of stromal and cancer cell CXCL16 in 266 NGutwein et al. studied CXCL16 and CXCR6 expression
in renal cancer, and reported low CXCL16 expression to
be linked to decreased overall survival [27]. Interestingly,
both normal lung [22] and renal [23] tissue show high
endogenous CXCL16 expression, which may suggest that
reduced or aberrant CXCL16 expression is linked toCXCL16 in 301 NSCLC patients. b. Disease specific survival curve
SCLC patients
Table 3 Results of Cox regression analyses for clinicopathological
factors and CXCL16 in stromal cells (model 1) and co-expression
of CXCL16 in cancer and stromal cells (model 2*)
Factor HR CI 95 % P
Tumor stage <0.001†
T1 1.00
T2 1.60 (0.97–2.64) 0.065
T3 3.80 (2.13–6.77) <0.001
Nodal stage <0.001†
N0 1.00
N1 2.01 (1.30–3.11) 0.002
N2 3.08 (1.74–5.44) <0.001
Differentiation 0.009†
Well 1.00
Poor 1.17 (1.12–3.85) 0.020
Moderate 2.08 (0.63–2.20) 0.618
Performance status 0.040†
0 1.00
1 1.52 (1.02–2.26) 0.040
2 2.15 (0.94–4.91) 0.069
Vascular infiltration
No 1.00
Yes 1.70 (1.01–2.87) 0.046
Histology <0.001†
Squamous carcinoma 1.00
Adenocarcinoma 2.23 (1.48–3.35) <0.001
Large cell carcinoma 0.80 (0.39–1.66) 0.555
CXC16 stromal cells
Low 1
High 0.55 (0.35–0.87) 0.011
CXCL16 cancer and stromal cells* 0.031†
Low/Low 1.00
Low/High + High/Low 0.57 (0.35–0.93) 0.023
Low/Low 0.42 (0.20–0.88) 0.022
†Overall significance as prognostic marker. HR, hazard ratio; CI 95 %, 95 %
confidence interval
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dogenous CXCL16 expression is a factor in the develop-
ment of NSCLC is further supported by the study
conducted by Mehan et al., which showed reduced
CXCL16 protein levels in NSCLC tissue compared to
normal tissue [28]. Moreover, the increased proliferation
we observed when CXCL16 was knocked down using
siRNA suggest a negative influence of CXCL16 on
NSCLC development. CXCL16, being a transmembrane
chemokine, has previously been shown to be involved in
cell adhesion through binding to CXCR6 [18, 35]. Lossof cell adhesion may therefore contribute to explaining
why CXCL16 knockdown leads to increased cell prolif-
eration through the loss of contact inhibition. De-
creased cell adhesion upon loss of CXCL16 expression
needs yet to be experimentally confirmed, but if it in-
deed takes place, it might promote detachment of sin-
gle cancer cells, their migration, and establishment
elsewhere as metastatic foci, thus contributing to
worse prognosis.
CXCL16 and CXCR6 are up-regulated in many can-
cers, and increased expression has been linked to
more aggressive disease and advanced tumor stage
[25, 36, 37], though few studies have shown increased
expression to be independently linked to reduced sur-
vival. A recent study of CXCR6 in resected hepatocel-
lular carcinoma found high CXCR6 expression to be
associated with reduced survival in a multivariate
model, through stimulation of a pro-inflammatory
tumor microenvironment [25]. In contrast, loss of
CXCR6 expression on NKT-cells resulted in increased
liver metastasis in a murine model [38]. Our results
do not indicate a prognostic role for CXCR6 in
NSCLC, though it was highly expressed in many
NSCLC tissue cores.
We did not observe CXCR6 expression on cells in the
tumor stroma. CXCR6 has previously been reported to
be involved in T cell recruitment to the lung [39], never-
theless no staining for CXCR6 was seen on infiltrating
lymphocytes in our TMAs. While expression has been
reported on T-cells in inflammatory lung disease such as
sarcoidosis [40], our result indicate that CXCR6 is not
expressed to an appreciable degree in infiltrating im-
mune cells in NSCLC.
Chemokines containing the ELR motif (ELR+) are
known to promote angiogenesis [41]. Despite being
ELR negative, CXCL16 has been shown to be an angio-
genic factor for recruitment of human umbilical vein
endothelial cells [24] and an important mediator of
angiogenesis in rheumatoid arthritis [42]. In prostate
cancer cell lines, CXCL16 induced the expression of
progangiogenic cytokines IL-8 and VEGF, while
CXCR6 expression on implanted tumor cells lead to
increased blood vessel formation in mice [36]. Simi-
larly, knockdown of CXCR6 leads to reduced angiogen-
esis in murine hepatocellular carcinoma [25]. However,
we did not observe a significant association between
CXCR6 and CXCL16 expression and markers of angio-
genesis in NSCLC.
The extracellular domain of CXCL16 can be proteo-
lytically cleaved by the disintegrin-like metalloproteinase
ADAM10, yielding a soluble form (sCXCL16) [43]. Hu
et al. reported that sCXCL16 increased the invasive
capacity of NSCLC cells, which suggests that CXCL16
may have different roles in lung cancer depending on
Fig. 4 Knockdown of CXCL16 with siRNA caused activation of proliferation compared to the negative scrambled control in NSCLC cell lines A549
and NCI-H460. Cells were trypsinized briefly until detached, resuspended in complete growth media and counted. According to the manufacturer’s
instructions, cells were seeded in duplicates into E-plates 16 after baseline measurement. Plates were incubated for 1 hour at room temperature, and
then placed into the RTCA DP instrument located in an incubator preserving same temperature and CO2 concentration as were used for routine
cultivation of the cells. siRNA transfection mix was added to the cells 6 hours after seeding, and left there for 4 hours. Subsequently, the transfection
mix was replaced with regular growth media. Cell index (arbitrary unit reflecting the cell-sensor impedance) was measured every 15 minutes during
the first 4 hours for better resolution at attachment and spreading phase. Further measurements were taken every 30 minutes. Doubling times were
calculated with RTCA software 1.2 (Roche). ± S.D of 4 technical replicates are shown. * P <0.001
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recent study in ovarian cancer, high serum sCXCL16
was linked to poor prognosis [45], whereas tumor
CXCL16 and CXCR6 were not associated with survival.
In colorectal cancer, high tumor CXCL16 expression has
been correlated with a favorable prognosis [30], while
high sCXCL16 is linked to recurrence [46]. The relation-
ship between serum sCXCL16 and tissue CXCL16 re-
mains unknown in NSCLC, and should be scrutinized in
future studies.
Conclucions
We have shown that high stromal cell CXCL16 expres-
sion and combined high stromal and cancer cell
CXCL16 are independent positive prognostic factors in
NSCLC. Our finding is supported by the fact that knock-
down of CXCL16 results in increased cell proliferation
in NSCLC cell lines.Competing interests
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